(Q37946702)

25 August 2017

title

Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma (English)

1 reference

25 August 2017

1 reference

Masahiro Abe

1

1 reference

25 August 2017

language of work or name

1 reference

18 October 2011

1 reference

International Journal of Hematology

25 August 2017

published in

1 reference

25 August 2017

volume

94

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

334-343

1 reference

Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma

25 August 2017

cites work

1 reference

12 December 2020

The microenvironment and molecular biology of the multiple myeloma tumor.

1 reference

12 December 2020

The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor/proteoglycan signaling axis in osteoblasts

1 reference

12 December 2020

Very late antigen (VLA) expression by normal and neoplastic human plasma cells; including an assessment of antibodies submitted to the Vth International Workshop on Leucocyte Differentiation Antigens using human myeloma cell lines

1 reference

12 December 2020

Pathogenesis of myeloma

1 reference

12 December 2020

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

1 reference

12 December 2020

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

1 reference

12 December 2020

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

1 reference

12 December 2020

Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.

1 reference

12 December 2020

1 reference

12 December 2020

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

1 reference

12 December 2020

Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment

1 reference

12 December 2020

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

1 reference

12 December 2020

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

1 reference

12 December 2020

Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production

1 reference

12 December 2020

RANKL-RANK signaling in osteoclastogenesis and bone disease

1 reference

12 December 2020

Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.

1 reference

12 December 2020

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma

1 reference

12 December 2020

Anti-myeloma activity of pamidronate in vivo

1 reference

12 December 2020

Cancer and the microenvironment: myeloma-osteoclast interactions as a model

1 reference

12 December 2020

Role of decorin in the antimyeloma effects of osteoblasts

1 reference

12 December 2020

Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.

1 reference

12 December 2020

The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells

1 reference

12 December 2020

A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.

1 reference

12 December 2020

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

1 reference

12 December 2020

An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma.

1 reference

12 December 2020

Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma

1 reference

12 December 2020

HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo

1 reference

12 December 2020

The role of the insulin-like growth factor 1 receptor axis in multiple myeloma

1 reference

12 December 2020

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

1 reference

12 December 2020

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

1 reference

12 December 2020

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

1 reference

12 December 2020

Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation

1 reference

12 December 2020

Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma

1 reference

12 December 2020

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

1 reference

12 December 2020

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

1 reference

12 December 2020

Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton

1 reference

12 December 2020

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

1 reference

12 December 2020

Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma

1 reference

12 December 2020

The tumor microenvironment: focus on myeloma

1 reference

12 December 2020

Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma

1 reference

12 December 2020

Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival

1 reference

12 December 2020

Wnt signaling: a common theme in animal development

1 reference

12 December 2020

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

1 reference

12 December 2020

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo

1 reference

12 December 2020

Angiogenesis in multiple myeloma

1 reference

12 December 2020

WNTs modulate cell fate and behavior during vertebrate development

1 reference

12 December 2020

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

1 reference

12 December 2020

Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways

1 reference

12 December 2020

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

1 reference

12 December 2020

Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma.

1 reference

12 December 2020

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys

1 reference

12 December 2020

First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro

1 reference

12 December 2020

HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

1 reference

12 December 2020

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma

1 reference

12 December 2020

Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease

1 reference

12 December 2020

Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc

1 reference

12 December 2020

A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma

1 reference

12 December 2020

Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma

1 reference

12 December 2020

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

1 reference

12 December 2020

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

1 reference

12 December 2020

The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms

1 reference

12 December 2020

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

1 reference

12 December 2020

Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma

1 reference

12 December 2020

Pathogenesis of myeloma bone disease

1 reference

12 December 2020

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

1 reference

12 December 2020

Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various cl

1 reference

12 December 2020

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

1 reference

12 December 2020

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

1 reference

12 December 2020

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

1 reference

12 December 2020

Bone marrow mesenchymal stem cells are abnormal in multiple myeloma

1 reference

12 December 2020

Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts.

1 reference

12 December 2020

The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells

1 reference

12 December 2020

Anti-tumor activity of pamidronate in human multiple myeloma

1 reference

12 December 2020

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines

1 reference

12 December 2020

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

1 reference

12 December 2020

Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model

1 reference

12 December 2020

Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells

1 reference

12 December 2020

BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma

1 reference

12 December 2020

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

1 reference

12 December 2020

Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation

1 reference

12 December 2020

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

1 reference

12 December 2020

Osteoclasts are important for bone angiogenesis

1 reference

12 December 2020

Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth

1 reference

12 December 2020

Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease

1 reference

12 December 2020

Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival

1 reference

12 December 2020

RANK ligand and osteoprotegerin in myeloma bone disease.

1 reference

12 December 2020

Potential role of insulin-like growth factor binding protein-4 in the uncoupling of bone turnover in multiple myeloma

1 reference

12 December 2020

Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.

1 reference

12 December 2020

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

12 December 2020

Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.

1 reference

12 December 2020

Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells

1 reference

12 December 2020

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

1 reference

12 December 2020

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

1 reference

12 December 2020

Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis

1 reference

12 December 2020

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

1 reference

12 December 2020

Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis

1 reference

12 December 2020

1 reference

12 December 2020

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

1 reference

12 December 2020

Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts

1 reference

12 December 2020

Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth

1 reference

12 December 2020

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.

1 reference

12 December 2020

Induction of chemokines and chemokine receptors CCR2b and CCR4 in authentic human osteoclasts differentiated with RANKL and osteoclast like cells differentiated by MCP-1 and RANTES.

1 reference

12 December 2020

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

1 reference

12 December 2020

Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors

1 reference

12 December 2020

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

1 reference

12 December 2020

Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients

1 reference

12 December 2020

The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts.

1 reference

12 December 2020

Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1.

1 reference

12 December 2020

10.1007/S12185-011-0949-X

Identifiers

DOI

1 reference

25 August 2017

1 reference